Taiwan-based vaccine maker Medigen will conduct a Phase 3 clinical trial for its COVID-19 vaccine in Europe once it has received approval from European authorities, which would help pave the way for its entry into European and other international markets, the company announced Wednesday.
(Full text of the story is now in CNA English news archive. To view the full story, you will need to be a subscribed member of the CNA archive. To subscribe, please read here.)
Latest
- Society
- Society
Police seeking man who threw firecrackers into car after traffic dispute
10/15/2025 03:04 PM - Politics
U.S. arms sales likely after Taiwan passes special defense budget: Expert
10/15/2025 03:03 PM - Business
Taiwan shares close up 1.8%
10/15/2025 02:33 PM - Business
IMF raises Taiwan's 2025 growth forecast to 3.7%
10/15/2025 01:33 PM